Rejuvenate Biomed

  • Home
  • Team
  • History
  • News
  • Events
  • Contact
  • Home
  • Team
  • History
  • News
  • Events
  • Contact
Home News

Stay up-to-date about our progress and other news

Advisory Board endorses Clinical Ph 2b strategy

Rejuvenate Biomed organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate RJx-01 in sarcopenia.

LEARN MORE

Groundbreaking clinical trial started

The first clinical trial with RJx-01 has started in disuse-induced muscle atrophy, marking Rejuvenate Biomed’s maturation to a clinical-stage company.

LEARN MORE

€15.7 million Series B round secured

This round was led by Rejuveron Life Sciences and Vesalius Biocapital. The funding is being used to accelerate the clinical development of RJx-01.

LEARN MORE

Preclinical data reviewed by Scientific Advisory Board

The SAB concluded that the preclinical data of RJx-01 demonstrate proof-of-principle for sarcopenia, and show potential in multiple other muscle- and non-muscle-related disorders.

LEARN MORE

Committed to a sustainable future

After identifying 5 core Sustainable Development Goals, Rejuvenate Biomed defined company actions to reach these goals for a sustainable future.

LEARN MORE
  • 1
  • 2
  • 3
  • 4
  • 5

Rejuvenate Biomed

Rejuvenate Biomed is a clinical-stage company developing combination drugs to promote healthy aging.

LET'S TALK

Office
Wetenschapspark 13
3590 Diepenbeek
Belgium

View map

Lab
Agoralaan building Abis
3590 Diepenbeek
Belgium

View map

info@rejuvenatebiomed.com

© Copyright 2023 Rejuvenate Biomed NV. All Right Reserved.
  • Privacy Policy
  • Cookie Policy

This website uses cookies to enhance your browsing experience. More information.